|
Sources/
Authors
|
Included
Cost
|
Study
perspective
|
Cost Effective Ratio
|
Discount
Rate for cost
and outcome
|
Study Model
|
|
Chen and
et.al
|
Direct
medical
cost
|
N/A
|
Biennial: $26 750 (34903a) per life-year
gained, and $17 833(23268a) per QALY. fiveyearly
screening: $10 531(13741a) per lifeyear
gained and $17 113(22329a) per QALY
|
3%
|
Markov Monte
Carlo Simulation
Model
|
|
Lee, D. S. et
al
|
Direct
medical
cost
|
Health system
perspective
|
The cost of community screening are greater
than the cost of diabetes without screening
ICER(-)
|
3%
|
Monte Carlo
simulation Mode
|
|
Kahn R. and
et al
|
Direct
medical
Cost
|
Health service
or delivery
system
|
Five screening strategies had costs per QALY
of about US$10 500. 45 years and every year
$15 509, at 60 years and every 3 years $25
738, at 30 years and repeated every 6 months;
$40 778
3%
|
Archimedes
model
|
|
Schaufler, T.
M. and et al
|
Direct
medical
cost
|
German system
of health
|
insurance
ICER: $892.5 per QALY for lifestyle intervention,
$316.33 per QALY for prevention with
metformin
|
Cost 5% /
Outcome (0
|
Markov Monte
Carlo Simulation
Mode
|
|
Hoerger, T.
J. et al
|
Direct
medical
cost
|
Health care
system
|
ICER for universal screening $126238
(150735a), $121965 (145633a), $62934
(75146a), $59183(70668a) and $48146
(57489a) and targeting screening
$87,096(103997a), $46,881 (55978a),
$34,375(41046a), $31,228 (37288a) and
$32,106 (38336a) for age at 35, 45, 55, 65 and
75 years respectively
|
3%
|
Markov model
|
|
Gillies CL.
et al
|
Direct
Medical
Cost
|
UK health
Care System
|
ICER: £14 150 (€17 560; $27 860 (29557a))
for screening DM, £6242 ($12290(13038a)) for
screening for DM and IGT followed by lifestyle
interventions, and £7023 ($13828
(14670a)) for screening for DM and IGT followed
by pharmacological intervention
|
3.5%
|
hybrid decision
tree/Markov
model was
developed to
simulate the long
term effects
|
